Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor

Charles Brink, Sven-Erik Dahlén, Jeffrey Drazen, Jilly F. Evans, Douglas W. P. Hay, G. Enrico Rovati, Charles N. Serhan, Takao Shimizu and Takehiko Yokomizo
Pharmacological Reviews March 2004, 56 (1) 149-157; DOI: https://doi.org/10.1124/pr.56.1.4
Charles Brink
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sven-Erik Dahlén
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Drazen
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jilly F. Evans
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas W. P. Hay
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Enrico Rovati
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles N. Serhan
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takao Shimizu
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takehiko Yokomizo
Centre National de la Recherche Scientifique UMR 7131, Hôpital Broussais, Bâtiment Les Mariniers, Paris, France (C.B.); Unit for Experimental Asthma and Allergy, The National Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (S.-E.D); Harvard Medical School, Brigham and Woman's Hospital, Boston, Massachussetts (J.M.D.); Department of Pharmacology, Merck & Co., West Point, Pennsylvania (J.F.E.); GlaxoSmithKline, King of Prussia, Pennsylvania (D.W.P.H.); Division of Molecular Pharmacology, Pharmacological Sciences, Milan, Italy (G.E.R.); Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesia Research Laboratory, Brigham and Woman's Hospital/Harvard Medical School, Boston, Massachusetts (C.N.S.); and Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Tokyo, Bunkyo-Ko, Tokyo, Japan (T.S., T.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Oxoeicosanoids are a family of biologically active arachidonic acid derivatives that have been intimately linked with cellular migration. These metabolites are not only potent chemotaxins but also elicit oxygen radical production as well as induce secretory events in different cells. The most potent native ligand reported is 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE), and the cell membrane receptor activated has now been cloned. This receptor is distinct from those receptors activated by either the prostaglandins or the leukotrienes. The purpose of this review is to briefly summarize the molecular evidence and highlight the significance of this receptor. In addition, an official nomenclature for this oxoeicosanoid receptor is proposed.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 56 (1)
Pharmacological Reviews
Vol. 56, Issue 1
1 Mar 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor

Charles Brink, Sven-Erik Dahlén, Jeffrey Drazen, Jilly F. Evans, Douglas W. P. Hay, G. Enrico Rovati, Charles N. Serhan, Takao Shimizu and Takehiko Yokomizo
Pharmacological Reviews March 1, 2004, 56 (1) 149-157; DOI: https://doi.org/10.1124/pr.56.1.4

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

International Union of Pharmacology XLIV. Nomenclature for the Oxoeicosanoid Receptor

Charles Brink, Sven-Erik Dahlén, Jeffrey Drazen, Jilly F. Evans, Douglas W. P. Hay, G. Enrico Rovati, Charles N. Serhan, Takao Shimizu and Takehiko Yokomizo
Pharmacological Reviews March 1, 2004, 56 (1) 149-157; DOI: https://doi.org/10.1124/pr.56.1.4
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Overview
    • II. Introduction
    • III. Biosynthesis of Oxoeicosanoids
    • IV. Nomenclature for Oxoeicosanoid Receptors
    • V. Molecular Characteristics of Oxoeicosanoid Receptors
    • VI. Significance of Oxoeicosanoid Receptors
    • VII. Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Heterodimerization of G Protein-Coupled Receptors: Specificity and Functional Significance
  • Stem Cell Approaches for the Treatment of Renal Failure
  • Gastrointestinal Function Regulation by Nitrergic Efferent Nerves
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics